In this regard, ABT-199, S63845 (MCL-1 inhibitor), and A-1331852 (BCL-xL inhibitor) have been described to affect ∆ψm in hematological malignancies accompanied by swollen mitochondria, rupture of the mitochondrial outer membrane as well as loss of cristae structure (Henz et al. 2019). This evidence concerns the gene MCL1 and hematologic disorder.